Neurocrine Biosciences, Inc. (NASDAQ:NBIX) insider Darin Lippoldt sold 9,900 shares of the firm’s stock in a transaction that occurred on Wednesday, November 15th. The stock was sold at an average price of $73.05, for a total transaction of $723,195.00. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.
Neurocrine Biosciences, Inc. (NBIX) opened at $72.28 on Friday. The company has a quick ratio of 14.37, a current ratio of 14.38 and a debt-to-equity ratio of 1.05. Neurocrine Biosciences, Inc. has a 1-year low of $37.35 and a 1-year high of $75.98.
Neurocrine Biosciences (NASDAQ:NBIX) last released its quarterly earnings results on Wednesday, November 1st. The company reported ($0.13) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.49) by $0.36. The firm had revenue of $60.77 million during the quarter, compared to analysts’ expectations of $29.38 million. During the same period in the prior year, the firm posted ($0.43) earnings per share. equities analysts forecast that Neurocrine Biosciences, Inc. will post -1.74 EPS for the current year.
WARNING: This story was originally published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this story on another website, it was stolen and republished in violation of United States and international copyright and trademark laws. The correct version of this story can be viewed at https://ledgergazette.com/2017/11/19/darin-lippoldt-sells-9900-shares-of-neurocrine-biosciences-inc-nbix-stock.html.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. First Trust Advisors LP grew its holdings in Neurocrine Biosciences by 29.0% in the third quarter. First Trust Advisors LP now owns 782,685 shares of the company’s stock worth $47,963,000 after purchasing an additional 176,136 shares during the last quarter. Canada Pension Plan Investment Board lifted its stake in shares of Neurocrine Biosciences by 49.7% during the second quarter. Canada Pension Plan Investment Board now owns 24,700 shares of the company’s stock worth $1,136,000 after buying an additional 8,200 shares during the period. Artisan Partners Limited Partnership acquired a new stake in shares of Neurocrine Biosciences during the second quarter worth $15,981,000. Davidson Kempner Capital Management LP acquired a new stake in shares of Neurocrine Biosciences during the second quarter worth $3,639,000. Finally, California Public Employees Retirement System lifted its stake in shares of Neurocrine Biosciences by 2.2% during the second quarter. California Public Employees Retirement System now owns 179,300 shares of the company’s stock worth $8,248,000 after buying an additional 3,900 shares during the period.
Several equities analysts recently issued reports on NBIX shares. Robert W. Baird reissued an “outperform” rating and set a $66.00 price objective on shares of Neurocrine Biosciences in a report on Thursday, September 21st. Jefferies Group LLC reissued a “buy” rating and set a $69.00 price objective (up from $66.00) on shares of Neurocrine Biosciences in a report on Tuesday, October 3rd. Leerink Swann reissued an “outperform” rating and set a $83.00 price objective (up from $72.00) on shares of Neurocrine Biosciences in a report on Thursday, November 2nd. Cowen and Company reissued an “outperform” rating and set a $65.00 price objective (up from $60.00) on shares of Neurocrine Biosciences in a report on Wednesday, August 9th. Finally, Barclays PLC lifted their price objective on shares of Neurocrine Biosciences from $75.00 to $85.00 and gave the company an “overweight” rating in a report on Thursday, November 2nd. One equities research analyst has rated the stock with a hold rating and eighteen have issued a buy rating to the stock. Neurocrine Biosciences has an average rating of “Buy” and a consensus target price of $78.88.
About Neurocrine Biosciences
Neurocrine Biosciences, Inc is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson’s disease.
Receive News & Ratings for Neurocrine Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.